June 3, 2026
Onco-Innovations Limited
ISIN: CA68237C1059
Onco-Innovations Advances 1kg Scale-Up of B4 Precursor Supporting ONC010 Manufacturing and Clinical Development Program
Also Announces Marketing Program Vancouver, Canada – June 2, 2026 – Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H, WKN: A3EKSZ) ("Onco" or the "Company”) announces, further to its news...
Read more >>Onco-Innovations Engages Investment Bank to Pursue Nasdaq Cross-listing and Potential Concurrent Equity Offering
Vancouver, Canada – December 07, 2025 – Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H, WKN: A3EKSZ) (“Onco” or the “Company”) is pleased to announce that it has engaged a U.S. investment bank to serve as its capital markets advisor in connection with the Company’s intention to pursue a...
Read more >Onco-Innovations Attends University of Alberta’s 2025 Innovation Awards
Vancouver, Canada – November 25, 2025 – Onco-Innovations Limited (CBOE CA: ONCO) (Frankfurt: W1H, WKN: A3EKSZ)(OTCQB: ONNVF) ("Onco" or the "Company") is pleased to announce that it was invited to attend the University of Alberta’s 2025 Innovation Awards in Edmonton, Alberta, which were held on November 21, 2025. The annual...
Read more >Onco-Innovations Advances Optimization and Scale-Up of Its PNKP Inhibitor Technology with Dalton Pharma Services to Support Future Phase 1 Clinical Studies
Vancouver, Canada – November 20, 2025 – Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H, WKN: A3EKSZ) ("Onco" or the "Company”) is pleased to announce that its manufacturing partner, Dalton Pharma Services (“Dalton”), has initiated process optimization and intermediate scale-up activities for A83B4C63, the Company’s proprietary PNKP Inhibitor Technology....
Read more >Onco-Innovations Advances AI and Quantum Drug Discovery with Kuano Collaboration to Accelerate PNKP Inhibitor Technology Development
Vancouver, Canada – November 18, 2025 – Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H, WKN: A3EKSZ) ("Onco" or the "Company”) is pleased to announce that it is initiating a pilot project with Kuano Ltd. (Kuano) to accelerate development of Onco’s PNKP Inhibitor Technology (also known as A83B4C63). This...
Read more >